Detalhe da pesquisa
1.
A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
Oncotarget
; 7(14): 18851-64, 2016 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26958811